Trial Profile
A Study to Evaluate the Incidence, Disease Characteristics, Response Rates and Outcome of Multiple Myeloma of the Central Nervous System(CNS-MM) Patients Treated with Bortezomib-based and/or Immunomodulator Drug (Thalidomide, Lenalidomide)-based Regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Feb 2016 New trial record